Pfizer, Sanofi, Vertex Pharmaceuticals, Merck & Co and Amgen are in line for exits after the immunotherapy developer filed to go public.
US-based immunotherapy developer Kymera Therapeutics has filed for a $100m initial public offering that could enable pharmaceutical firms Merck & Co, Amgen, Pfizer, Sanofi and Vertex Pharmaceuticals to exit.
Incubated by venture capital firm Atlas Venture, Kymera is working on small molecule drugs intended to combat cancer and inflammatory diseases by degrading disease-causing proteins.
Part of the IPO proceeds will advance KT-474, which is being developed to treat rheumatoid arthritis, an inflammatory skin disease called HS and a skin…
